Wuhan Hiteck Biological Pharma Co Ltd (300683) — Capital Reinvestment Ratio
Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Capital Reinvestment Ratio of 1.14x as of September 2024, meaning it reinvests 1% of its operating cash flow (CN¥4.86 Million) in capital expenditures (CN¥5.52 Million). Check 300683 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Wuhan Hiteck Biological Pharma Co Ltd Capital Reinvestment Ratio (2013–2024)
This chart tracks Wuhan Hiteck Biological Pharma Co Ltd's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see 300683 cash flow metrics.
Annual Capital Reinvestment Ratio for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
Year-by-year Capital Reinvestment Ratio for Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024. See Wuhan Hiteck Biological Pharma Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.90x | CN¥22.69 Million | CN¥43.08 Million | ▼ -94.0% |
| 2023 | 31.51x | CN¥5.31 Million | CN¥167.44 Million | ▲ +860.5% |
| 2022 | 3.28x | CN¥53.03 Million | CN¥173.97 Million | ▼ -84.0% |
| 2021 | 20.44x | CN¥12.09 Million | CN¥247.11 Million | ▲ +1009.2% |
| 2019 | 1.84x | CN¥63.03 Million | CN¥116.15 Million | ▲ +249.9% |
| 2018 | 0.53x | CN¥73.42 Million | CN¥38.67 Million | ▲ +96.6% |
| 2017 | 0.27x | CN¥83.08 Million | CN¥22.25 Million | ▲ +74.8% |
| 2016 | 0.15x | CN¥143.86 Million | CN¥22.05 Million | ▲ +79.9% |
| 2015 | 0.09x | CN¥159.89 Million | CN¥13.62 Million | ▼ -26.3% |
| 2014 | 0.12x | CN¥135.40 Million | CN¥15.64 Million | ▼ -43.5% |
| 2013 | 0.20x | CN¥76.82 Million | CN¥15.71 Million | — |